Send to

Choose Destination
Oncoimmunology. 2012 Jan 1;1(1):103-105.

Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy.

Author information

Institut Curie; Centre de Recherche; Paris, France ; INSERM; U93; Paris, France.


Antibody-dependent cell cytotoxicity (ADCC) is critical in monoclonal antibody (mAb)-mediated cancer therapy. We recently showed that a tumor-specific mAb in combination with cyclophosphamide inhibited tumor cell growth and induced ADCC-synapses between tumor and effector cells in vivo, opening perspectives to enhance anti-tumor responses by manipulating the immune system.

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center